According to research by Industrial Info Resources, in addition to the scores of drugs currently being churned out by the pharmaceutical-biotechnology industry, the group is nearly as prolific in turning out new manufacturing plants and research facilities.
A current analysis derived from the Pharmaceutical Tracker - Online Database has revealed that there are 78 plants, carrying a total investment value of $6.3 billion, in various stages of construction across North America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze